The European Bank for Reconstruction and Development has agreed to invest 6 million euros to support European Metals Holdings' (ASX:EMH) development of the Cinovec lithium project in the Czech Republic. Executive Chairman Keith Coughlan discusses the significance of the placement and the momentum behind lithium in Europe.
Copyright 2023 – Finance News Network
24 Nov 2020 - Mitchell Services Limited (ASX:MSV) CEO Andrew Elf provides an update on the company's FY20 results, its strategy of becoming Australia’s leading drilling services provider and the robust state of the mining sector.
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
25 May 2021 - Skyfii Limited (ASX:SKF) CEO & Managing Director Wayne Arthur talks about the company's SaaS cloud-based solution that helps venues visualise, measure, predict and influence customer behaviour, creating better experiences for their visitors and customers.
04 Oct 2022 - Knosys Limited (ASX:KNO) Managing Director John Thompson discusses FY22 highlights, revenue drivers, growth investments, hybrid working tailwinds and the outlook for FY23.
18 Aug 2022 - eCargo Holdings Limited (ASX:ECG) Group CEO Lawrence Lun discusses the rationale for the sale of digital consultancy company Amblique, how the proceeds will be used, and the roadmap for the coming months.
25 Oct 2023 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses efficacy results for the company's glioblastoma therapy.
30 Jul 2024 - Andrew Penkethman - CEO & Managing Director - Ardea Resources (ASX:ARL) is an ASX-listed nickel resources company, with a large portfolio of 100%-controlled West Australian-based projects.
30 Mar 2022 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt discusses the company's LAG-3-related therapies, outlining future plans and expected data readouts for Immutep's lead drug, eftilagimod alpha.